Previous Article | Next Article 
Journal of Clinical Microbiology, November 2001, p. 4020-4025, Vol. 39, No. 11
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.11.4020-4025.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Emergence of G9 P[6] Human Rotaviruses in
Argentina: Phylogenetic Relationships among G9 Strains
Karin
Bok,1,*
Gustavo
Palacios,2
Karina
Sijvarger,3
David
Matson,4 and
Jorge
Gomez1
Viral Gastroenteritis
Laboratory,1 and Neuroviruses
Division2 National Institute of Infectious
Diseases, Buenos Aires, and Central Laboratory, Regional
Hospital, Ushuaia,3 Argentina, and
Center for Pediatric Research, Children's Hospital of The
King's Daughters, Eastern Virginia Medical School, Norfolk,
Virginia4
Received 17 January 2001/Returned for modification 3 April
2001/Accepted 9 September 2001
 |
ABSTRACT |
Because rotavirus diarrhea can be reduced through vaccination and
because current vaccine candidates provide protection against only the
most common G antigenic types (G1 to G4), detection of uncommon G types
is one of the main goals of rotavirus surveillance. After a 2-year
nationwide rotavirus surveillance study in Argentina concluded,
surveillance was continued and an increase of G9 prevalence in several
Argentine cities was detected. During this period G9 strains
predominated in the south, and a gradient of decreasing G9 prevalence
was observed from south to north (41 to 0%). Sequence analysis of gene
9, encoding the G antigen, showed that Argentine strains cluster with
most G9 isolates from other countries, showing less than 2% nucleotide
divergence among them, but are distinctive from them in that they
present some unique amino acid changes. Our results agree with reports
of increased G9 prevalence in other parts of the world, suggesting the
need to incorporate G9 into candidate rotavirus vaccines.
 |
INTRODUCTION |
Rotaviruses are the major cause of
severe gastroenteritis in infants and young children worldwide
(12, 26). Their genome includes 11 segments of
double-stranded RNA that are located inside a triple-layered virus
particle. Rotaviruses are classified into G and P types, according to
the genetic and antigenic diversity of the two outer capsid proteins
VP7 and VP4, respectively. At least 14 G types and 20 P types have been
identified (9).
Because the severity of disease can be reduced through vaccination,
several vaccines are under development to provide specific protection
against the most prevalent rotavirus G types, G1 to G4 (2, 3, 7,
11). However, patterns of G type distribution appear to be
changing, as less common rotavirus G types, such as G9, have been
reported recently to be circulating in the United States (F. E. Campos, P. Azimi, M. A. Staat, T. Berke, L. J. Jackson, D. I. Bernstein, D. Ward, L. K. Pickering, and D. O. Matson, Abstr. 37th Infect. Dis. Soc. Am. [IDSA], abstr. 702, 1999),
Malawi, Bangladesh, the United Kingdom, France, and Australia (6,
16, 17, 25, 27, 29). Although the tetravalent rhesus rotavirus vaccine (RRV) was recently withdrawn in the United States, the information available suggests that future vaccines might need to
incorporate additional antigenic specificities.
In Argentina, G9 rotaviruses were reported only at a very low
prevalence from October 1996 to September 1998 (0.4 and 0.8% each
year, respectively), during a nationwide rotavirus surveillance conducted by our laboratory (4). After that study
concluded, rotavirus surveillance continued at some locations in 1999 while a permanent surveillance system was being established.
Surprisingly, we detected an increase of G9 prevalence in several
Argentine cities during the 1998-1999 rotavirus season. Here, we
report the high prevalence of G9 strains in our country and present
results of epidemiological and virologic analysis of this emerging
rotavirus type.
 |
MATERIALS AND METHODS |
Surveillance system.
After the previous surveillance study
concluded (4), surveillance continued at seven sentinel
units (SUs) from September 1998 through June 1999, together with a
newly added SU in Ushuaia, mainly to continue monitoring of the
prevalence of rotavirus G and P types. SUs participating during this
period were placed in the following regions of Argentina (in the
indicated large cities): South (Ushuaia), Greater Buenos Aires (La
Plata and Buenos Aires), Center (Mendoza, Cordoba, and Rosario), and
North (Tucuman and Resistencia). A reference laboratory at the Viral
Gastroenteritis Laboratory (VGL) in the National Institute of
Infectious Diseases provided core support, collected data from the SUs,
and typed the rotavirus strains. Each SU consisted of a hospitalization site and a virology laboratory. A virologist and a pediatrician were
responsible for each SU.
The study was conducted in hospitalized patients, under 3 years of age,
who presented with diarrhea of less than 5 days' duration. The
diagnostic stool samples were collected within 24 h of admission, and patients transferred from another hospital were not included. The
patient form and the stool sample were sent to the virology laboratory
of the SU.
Rotavirus diagnosis.
Bulk stool specimens (at least 1 g) were received in the virology laboratory at each SU, where they were
kept at 4°C. They were tested for rotavirus within a week of
collection. Pathfinder (Kallestad, Austin, Tex.) or Rotazyme II (Abbott
Laboratories, Abbott Park, Ill.) kits were used following the
manufacturers' recommendations. Each of these assays is defined as a
confirmatory assay by the U.S. Food and Drug Administration, meaning
that they have >95% sensitivity and >95% specificity. After
rotavirus diagnosis was completed, positive samples were kept at
20°C until they were shipped to the VGL for further strain characterization.
Characterization of rotavirus strains.
Rotavirus prototype
strains Wa, DS1, ST3, K8, 69M, Ito (kindly provided by Roger Glass,
Centers for Disease Control and Prevention, Atlanta, Ga.), OSU
(Fernando Fernandez, INTA, Buenos Aires, Argentina) and F45 were
cultivated in MA104 cells and used as controls for typing assays.
Genotyping was carried out using a nested reverse transcription
(RT)-PCR method, as previously described, with some modifications
(8, 14). Rotavirus RNA was extracted from 10% fecal
suspensions using TRIzol (Life Technologies, Inc., Frederick, Md.),
following the manufacturer's instructions. Gene 9 was amplified using
a pair of generic primers (Beg and End), and then a pool of internal
primers for G1, G2, G3, G4, G5, and G9, with consensus primer 9C1, was
used. P genotypes were determined by a similar RT-PCR strategy
(10). Agarose gel electrophoresis and ethidium bromide
staining were performed to visualize resulting bands.
Sequence analysis.
Partial gene 9 (encoding VP7) DNA
sequence was obtained from amplicons generated in the first round of
the G-typing RT-PCR (28). cDNA was purified with a
commercial kit (MicroSpin S-400 HR; Amersham Pharmacia Biotech; or
Wizard PCR Preps; Promega) and then sequenced (Thermo Sequenase Cy 5 Dye Terminator Kit, ALFexpress automated sequencer; Amersham Pharmacia
Biotech; or ABI PRISM Big Dye Terminator Cycle Sequencing Ready
Reaction Kit; Perkin-Elmer, Applied Biosystems).
Phylogenetic analysis was performed on VP7 sequences (nucleotides 82 to
781) and on partial deduced amino acid sequences of the VP7 gene (amino
acids 12 to 244). Alignments were obtained with Clustal X and analyzed
using DNAdist or Protdist and Kitsch of the PHYLIP software package.
The statistical significance of phylogenies constructed was estimated
using the Seqboot program by bootstrap analysis with 100 pseudoreplicate data sets. The tree was displayed with Treeview
program. The sequences used for comparison are available in the
GenBank/EMBL database.
Nucleotide sequence accession numbers.
The Argentine VP7
gene sequences described in this study have been deposited in the
GenBank sequence data base, and the strains and their gene sequence
accession numbers respectively, are as follows: Ush1754,
AF323707; Ush1755, AF323708; Ush2029, AF323709; Ush1574,
AF323710; Ush1575, AF323711; Ush1490, AF323712; Ush1753,
AF323713; BA1977, AF323714; BA1939, AF323715; LP1552, AF323716;
LP1550, AF323717M; Men 1742, AF323718; Men1740, AF323719.
 |
RESULTS |
Characterized samples.
A total of 88 rotavirus-positive fecal samples were characterized at the VGL from
September 1998 through June 1999. Unexpectedly, we found a significant
increase in the percentage of G9 strains at some SUs, with G9 becoming
the third most prevalent type, as shown by the results given in Table
1: G1 was the most prevalent (47%),
followed by G4 (28%) and G9 (18%). G9 was most common in the South
(Ushuaia), causing 41% of cases, less common in Greater Buenos Aires
(27%) and the Center (18%), and least common in the North, where only
G1 and G4 strains were present. This gradient of decreasing G9
prevalence was statistically significant (chi-square test for trend,
15.8; P < 0.001). Only two (2%) samples could not be
typed, and four samples (5%) were mixed infections.
All 16 G9 strains were associated to P[6], and 13 of them, which
presented a polyacrylamide gel electrophoresis-positive result, had identical short electropherotypes (Ush1490, LP1550, LP1552, Ush1574, Ush1575, Men1740, Men1742, Ush1753, Ush1754, Ush1755, BA1939, BA1977, Ush2029) (data not shown). G1 and G4 were associated with P[8].
Phylogenetic relationships.
We obtained partial gene 9 sequences for 13 G9 strains, including 7 from Ushuaia (Ush1490,
Ush1574, Ush1575, Ush1753, Ush1754, Ush1755, and
Ush2029), 4 from Greater Buenos Aires (BA1939, BA1977, LP1550,
and LP1552), and 2 from the Center (Men1740 and Men1742). Figure
1 shows the phylogenetic tree obtained
from the analysis of these and homologous published sequences. A tree
was also obtained from the analysis of nucleotide sequences, but
because of the very low divergence among strains, relationships were
more distinct in the protein analysis. Most worldwide G9 strains
grouped together with Argentine strains into one cluster, with less
than 2% nucleotide divergence among them, and just two pairs (Ush1754
and Ush1755; BA1977 and Ush1574) of Argentine strains grouped together,
with significant bootstrap values. Only three strains from Bangladesh (BD426, BD431, and BD524), two strains from India (INL1 and ING16), and
one strain from Reading, United Kingdom (UK63297), clustered separately, but these presented only 2 to 4% nucleotide divergence compared with Argentine strains. The high sequence conservation among
the G9 VP7 sequences is similar to that observed for other G types,
which exhibit >91% VP7 amino acid identity (20). The low
degree of divergence found among G9 strains agrees with the degree of
divergence found among G1, G2, G6, or G8 types in other studies
(18, 23, 24, 30). All the G9 strains analyzed in this
study were distantly related to the prototype Indian strain 116E, with
12 to 14% nucleotide divergence, demonstrating that this reference
strain is quite distinct from most circulating G9 strains. Similar
results were found when comparing these strains with prototype
G9 strain W161 (data not shown).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Phylogenetic analysis of the VP7 deduced amino acid
sequences of serotype G9 strains. A phylogenetic tree was constructed
based on the Kimura method of the PHYLIP package. Percentage bootstrap
values above 50% are shown at the branch nodes. Bold letters indicate
Argentine strains. IN, India; UK, United Kingdom; BD, Bangladesh; MW,
Malawi; US, United States; Men, Mendoza; Ush, Ushuaia; LP, La Plata;
BA, Buenos Aires.
|
|
Variation among G9 strains.
Although variation occurred
at low frequency, deduced VP7 amino acid sequences differed at several
sites among Argentine strains and also when compared with the reference
prototype strain IN116E (Fig. 2). In
comparison with IN116E, a total of 20 amino acid changes were
identified in the region of VP7 analyzed, of which 16 were present in
all Argentine samples. Moreover, 11 of these changes occurred in
regions of the VP7 protein (variable regions) that are normally highly
divergent among members of different G types. Some changes were unique
among the characterized strains such as at positions 42 and 51 in
Ush1754 and Ush1755 and at positions 217 and 230 in a strain from
Buenos Aires (BA 1977). One amino acid substitution unique and
consistent among the Argentine strains was found: at position 171, threonine present in every isolate but strain IN116E (which has an
alanine at this position) was replaced by an isoleucine.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
Deduced amino acid sequences of Argentine strains
compared to reference strain 116E. Amino acids underlined and in bold
letters indicate regions that are highly variable among G types.
|
|
 |
DISCUSSION |
In a countrywide surveillance network operating between
1996 and 1998, human rotavirus G9 strains was detected at a low
prevalence in Argentina (0.4% during 1996-1997 and 0.8% during
1997-1998) (4, 5). Continuation of the surveillance into
1999 revealed a sharp increase in G9 prevalence (18% overall), not
equally distributed across the country, being highest in the
south (41%) and lowest in the north (0%). Human rotavirus G9
strains had not been previously reported at high frequencies in Latin
American countries, except for a case report from Brazil during a
vaccine trial (21). The increased prevalence in Argentina
is consistent with what appears to be an extending global distribution
of this type (6, 16, 17, 25, 27).
The increased prevalence of G9 strains during the 10-month period made
it the third most prevalent G type during that period. This was
especially notable in Ushuaia, where the G9 prevalence at 41%
represents the highest G9 prevalence ever reported. It is also
interesting to note the gradient of decreasing G9 prevalence from south
to north. This gradient may be attributable to several reasons,
including the extremely different climate conditions in Ushuaia,
because it is the most southern city in our country or because it
attracts tourists not only from elsewhere in Argentina but also from
other countries, potentially enabling the introduction and emergence of
a new strain there.
G9 strains may not have been detected in previous studies in our
country due to the unavailability of monoclonal antibodies directed
against this type. A previous study conducted in Argentina from 1983 to
1985, in which rotavirus-positive samples were characterized using
monoclonal antibodies directed against G1 to G4 serotypes only,
detected 5.5% nontypeable strains (13). Moreover, there are studies reporting that some G4-specific monoclonal antibodies reacted with rotavirus G9 strains (29). Although another
study recently conducted in the southern region of Buenos Aires, based on RT-PCR characterization, did not detect any G9 strains, this may be
due to the restricted geographic area analyzed (1). Despite that, we confirmed the emergence of this type during 1998-1999 by continuing multisite surveillance and utilizing genotyping assays
capable of detecting G9 strains.
Many studies report differences among strains of the same genotype,
which often describe sublineages of the same G type (19, 22). Therefore, it is notable that several G9 strains from
distant parts of the world, such as the United Kingdom, the United
States, Malawi, and Argentina, clustered together in the phylogenetic analysis. The high degree of identity found among this group and the
fact that they are more closely related to each other than to reference
strain 116E suggest that the same strains are emerging all around the
world and that they are a recent introduction in the population.
Most strains from Ushuaia share distinctive changes located in highly
variable regions that may define a common antigenic pattern. A singular
amino acid substitution at position 171 was present only in all
Argentine strains. This pattern of substitution agrees with the
graphical representation of amino acid exchangeability according to
Argyle's method (15). This method assumes that depending
on the protein, 60 to 90% of the observed amino acid replacements
involve the nearest or second-nearest neighbors of the amino acid ring,
where alanine is followed by threonine and then by isoleucine. This
succession of amino acid changes is clearly shown in Fig. 2. The oldest
strain analyzed (IN116E) has at this position an alanine, which is then
replaced by a threonine (present in other non-Argentine strains) and
eventually by isoleucine, an amino acid present only in Argentine
strains, which are the newest isolates in this analysis. However, the
replacement of a less hydrophobic residue like threonine (
0.7
according to the Kyte and Doolittle scale) or alanine (1.8) by a highly
hydrophobic amino acid like isoleucine (4.5) shows that a generally
constrained property of proteins is being modified. Although this
change is not present in a highly variable region, where the major
neutralization epitopes have been identified (amino acids 87 to 99, 145 to 150, and 211 to 223), the substitution of amino acids with very
different properties may affect viral structure and protein properties. Considering the low degree of diversity among G9 strains, a single substitution that is found only in Argentine strains appears to identify our strains, because no other similar substitution was shared
by every strain from another country. The pattern of amino acid
exchangeability shown by Argyle's method is also valid for most
changes observed among strains analyzed (Fig. 2).
Finally, this study has limitations. Relatively few samples were
analyzed in some locations during a short study period, and so the
results may not accurately reflect the prevalence of G9 strains in the
studied population. The absence of G9 strains in the northern area of
the country may also be attributed to the same fact. Although we are
showing the increased prevalence of G9 strains in several locations
during 1999, it is possible that the emergence of this G type in
Ushuaia occurred prior to 1999, because this location was not included
in the first surveillance period (4). Despite that, our
results agree with the increasing reports of G9 strains in other parts
of the world, suggesting that the incorporation of this type into
candidate rotavirus vaccines should be considered. In addition, these
results emphasize the need to install a continual surveillance system
for rotavirus infections at several locations, in order to monitor the
prevalence of this or other emerging strains properly. This will
facilitate determination of the appropriate rotavirus vaccine
constituents at launch and subsequently.
 |
ACKNOWLEDGMENTS |
We thank all the professionals and nonprofessionals from the
Sentinel Units who kindly contributed to this study.
This work was partially supported by a grant from John Wyeth
Laboratories and a grant from the National Agency for the Advancement of Science (PICT' 98 no. 0503533 to J.G.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Departamento de
Virus, Instituto Nacional de Enfermedades Infecciosas, ANLIS, "Dr. Carlos G. Malbran," Av. Velez Sarsfield 563 (1281), Buenos Aires, Argentina. Phone: 54 11 43017428. Fax: 54 11 43025064. E-mail: kbok{at}anlis.gov.ar.
 |
REFERENCES |
| 1.
|
Arguelles, M. H.,
G. A. Villegas,
A. Castello,
A. Abrami,
P. D. Ghiringhelli,
L. Semorile, and G. Glikmann.
2000.
VP7 and VP4 genotyping of human group A rotavirus in Buenos Aires, Argentina.
J. Clin. Microbiol.
38:252-259[Abstract/Free Full Text].
|
| 2.
|
Bernstein, D. I.,
D. A. Sack,
E. Rothstein,
K. Reisinger,
V. E. Smith,
D. O'Sullivan,
D. R. Spriggs, and R. L. Ward.
1999.
Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial.
Lancet
354:287-290[CrossRef][Medline].
|
| 3.
|
Bishop, R. F.
1993.
Development of candidate rotavirus vaccines.
Vaccine
11:247-254[CrossRef][Medline].
|
| 4.
|
Bok, K.,
N. Castagnaro,
A. Borsa,
S. Nates,
C. Espul,
O. Fay,
A. Fabri,
S. Grinstein,
I. Miceli,
D. Matson, and J. Gomez.
2001.
Surveillance for rotavirus in Argentina.
J. Med. Virol.
65:190-198[CrossRef][Medline].
|
| 5.
|
Bok, K.,
N. C. Castagnaro,
N. E. Diaz,
A. Borsa,
M. R. Cagnoli,
S. Nates,
S. Yudowsky,
C. Espul,
H. Cuello,
O. Fay,
B. Brunet,
O. C. Ues,
R. Santoro,
S. Grinstein,
F. Gonzalez,
I. Miceli, and J. A. Gomez.
1999.
[Rotavirus laboratory network: results after one year of observation].
Rev. Argent. Microbiol.
31:1-12[Medline]. (In Spanish.)
|
| 6.
|
Bon, F.,
C. Fromantin,
S. Aho,
P. Pothier,
E. Kohli, and The Azay Group.
2000.
G and P genotyping of rotavirus strains circulating in France over a three-year period: detection of G9 and P[6] strains at low frequencies.
J. Clin. Microbiol.
38:1681-1683[Abstract/Free Full Text].
|
| 7.
|
Clements-Mann, M. L.,
M. K. Makhene,
J. Mrukowicz,
P. F. Wright,
Y. Hoshino,
K. Midthun,
E. Sperber,
R. Karron, and A. Z. Kapikian.
1999.
Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants.
Vaccine
17:2715-2725[CrossRef][Medline].
|
| 8.
|
Das, B. K.,
J. R. Gentsch,
Y. Hoshino,
S. Ishida,
O. Nakagomi,
M. K. Bhan,
R. Kumar, and R. I. Glass.
1993.
Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E.
Virology
197:99-107[CrossRef][Medline].
|
| 9.
|
Estes, M.
1996.
Rotaviruses and their replication, p. 1625-1655.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
|
| 10.
|
Gentsch, J. R.,
R. I. Glass,
P. Woods,
V. Gouvea,
M. Gorziglia,
J. Flores,
B. K. Das, and M. K. Bhan.
1992.
Identification of group A rotavirus gene 4 types by polymerase chain reaction.
J. Clin. Microbiol.
30:1365-1373[Abstract/Free Full Text].
|
| 11.
|
Gentsch, J. R.,
P. A. Woods,
M. Ramachandran,
B. K. Das,
J. P. Leite,
A. Alfieri,
R. Kumar,
M. K. Bhan, and R. I. Glass.
1996.
Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development.
J. Infect. Dis.
174:S30-S36.
|
| 12.
|
Glass, R. I.,
P. E. Kilgore,
R. C. Holman,
S. Jin,
J. C. Smith,
P. A. Woods,
M. J. Clarke,
M. S. Ho, and J. R. Gentsch.
1996.
The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden.
J. Infect. Dis.
174:S5-S11.
|
| 13.
|
Gomez, J.,
M. K. Estes,
D. O. Matson,
R. Bellinzoni,
A. Alvarez, and S. Grinstein.
1990.
Serotyping of human rotaviruses in Argentina by ELISA with monoclonal antibodies.
Arch. Virol.
112:249-259[CrossRef][Medline].
|
| 14.
|
Gouvea, V.,
R. I. Glass,
P. Woods,
K. Taniguchi,
H. F. Clark,
B. Forrester, and Z. Y. Fang.
1990.
Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens.
J. Clin. Microbiol.
28:276-282[Abstract/Free Full Text].
|
| 15.
|
Graur, D., and W. Li.
1999.
Fundamentals of molecular evolution, 2nd ed.
Sinauer Associates, Inc., Sunderland, Mass.
|
| 16.
|
Griffin, D. D.,
C. D. Kirkwood,
U. D. Parashar,
P. A. Woods,
J. S. Bresee,
R. I. Glass, and J. R. Gentsch.
2000.
Surveillance of rotavirus strains in the United States: identification of unusual strains. The National Rotavirus Strain Surveillance System collaborating laboratories.
J. Clin. Microbiol.
38:2784-2787[Abstract/Free Full Text].
|
| 17.
|
Iturriza-Gomara, M.,
D. Cubitt,
D. Steele,
J. Green,
D. Brown,
G. Kang,
U. Desselberger, and J. Gray.
2000.
Characterisation of rotavirus G9 strains isolated in the UK between 1995 and 1998.
J. Med. Virol.
61:510-517[CrossRef][Medline].
|
| 18.
|
Jayasinghe, S. M., and E. A. Palombo.
1999.
Genetic homogeneity of human serotype G1 rotaviruses isolated during a single epidemic season: implications for vaccine strategies.
Acta Virol.
43:53-55[Medline].
|
| 19.
|
Jin, Q.,
R. L. Ward,
D. R. Knowlton,
Y. B. Gabbay,
A. C. Linhares,
R. Rappaport,
P. A. Woods,
R. I. Glass, and J. R. Gentsch.
1996.
Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses.
Arch. Virol.
141:2057-2076[CrossRef][Medline].
|
| 20.
|
Kapikian, A. Z., and R. M. Chanock.
1996.
Rotaviruses, p. 1657-1708.
In
B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
|
| 21.
|
Linhares, A. C.,
Y. B. Gabbay,
J. D. Mascarenhas,
R. B. de Freitas,
C. S. Oliveira,
N. Bellesi,
T. A. Monteiro,
Z. Lins-Lainson,
F. L. Ramos, and S. A. Valente.
1996.
Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil.
Bull. W. H. O.
74:491-500[Medline].
|
| 22.
|
Maunula, L., and C. H. von Bonsdorff.
1998.
Short sequences define genetic lineages: phylogenetic analysis of group A rotaviruses based on partial sequences of genome segments 4 and 9.
J. Gen. Virol.
79:321-332[Abstract].
|
| 23.
|
Palombo, E. A., and R. F. Bishop.
1995.
Genetic and antigenic characterization of a serotype G6 human rotavirus isolated in Melbourne, Australia.
J. Med. Virol.
47:348-354[Medline].
|
| 24.
|
Palombo, E. A.,
R. Clark, and R. F. Bishop.
2000.
Characterisation of a "European-like" serotype G8 human rotavirus isolated in Australia.
J. Med. Virol.
60:56-62[CrossRef][Medline].
|
| 25.
|
Palombo, E. A.,
P. J. Masendycz,
H. C. Bugg,
N. Bogdanovic-Sakran,
G. L. Barnes, and R. F. Bishop.
2000.
Emergence of serotype G9 human rotaviruses in Australia.
J. Clin. Microbiol.
38:1305-1306[Free Full Text].
|
| 26.
|
Parashar, U. D.,
J. S. Bresee,
J. R. Gentsch, and R. I. Glass.
1998.
Rotavirus.
Emerg. Infect. Dis.
4:561-570[Medline].
|
| 27.
|
Ramachandran, M.,
J. R. Gentsch,
U. D. Parashar,
S. Jin,
P. A. Woods,
J. L. Holmes,
C. D. Kirkwood,
R. F. Bishop,
H. B. Greenberg,
S. Urasawa,
G. Gerna,
B. S. Coulson,
K. Taniguchi,
J. S. Bresee, and R. I. Glass.
1998.
Detection and characterization of novel rotavirus strains in the United States.
J. Clin. Microbiol.
36:3223-3229[Abstract/Free Full Text].
|
| 28.
|
Sanger, F.,
S. Nicklen, and A. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467[Abstract/Free Full Text].
|
| 29.
|
Unicomb, L. E.,
G. Podder,
J. R. Gentsch,
P. A. Woods,
K. Z. Hasan,
A. S. Faruque,
M. J. Albert, and R. I. Glass.
1999.
Evidence of high-frequency genomic reassortment of group A rotavirus strains in Bangladesh: emergence of type G9 in 1995.
J. Clin. Microbiol.
37:1885-1891[Abstract/Free Full Text].
|
| 30.
|
Zao, C. L.,
W. N. Yu,
C. L. Kao,
K. Taniguchi,
C. Y. Lee, and C. N. Lee.
1999.
Sequence analysis of VP1 and VP7 genes suggests occurrence of a reassortant of G2 rotavirus responsible for an epidemic of gastroenteritis.
J. Gen. Virol.
80:1407-1415[Abstract].
|
Journal of Clinical Microbiology, November 2001, p. 4020-4025, Vol. 39, No. 11
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.11.4020-4025.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Castello, A. A., Arguelles, M. H., Rota, R. P., Olthoff, A., Jiang, B., Glass, R. I., Gentsch, J. R., Glikmann, G.
(2006). Molecular Epidemiology of Group A Rotavirus Diarrhea among Children in Buenos Aires, Argentina, from 1999 to 2003 and Emergence of the Infrequent Genotype G12.. J. Clin. Microbiol.
44: 2046-2050
[Abstract]
[Full Text]
-
Teodoroff, T. A., Tsunemitsu, H., Okamoto, K., Katsuda, K., Kohmoto, M., Kawashima, K., Nakagomi, T., Nakagomi, O.
(2005). Predominance of Porcine Rotavirus G9 in Japanese Piglets with Diarrhea: Close Relationship of Their VP7 Genes with Those of Recent Human G9 Strains. J. Clin. Microbiol.
43: 1377-1384
[Abstract]
[Full Text]
-
Banyai, K., Gentsch, J. R., Schipp, R., Jakab, F., Bene, J., Melegh, B., Glass, R. I., Szucs, G.
(2004). Molecular epidemiology of human P[8],G9 rotaviruses in Hungary between 1998 and 2001. J Med Microbiol
53: 791-801
[Abstract]
[Full Text]
-
Hoshino, Y., Jones, R. W., Ross, J., Honma, S., Santos, N., Gentsch, J. R., Kapikian, A. Z.
(2004). Rotavirus Serotype G9 Strains Belonging to VP7 Gene Phylogenetic Sequence Lineage 1 May Be More Suitable for Serotype G9 Vaccine Candidates than Those Belonging to Lineage 2 or 3. J. Virol.
78: 7795-7802
[Abstract]
[Full Text]
-
Sanchez-Fauquier, A., Wilhelmi, I., Colomina, J., Cubero, E., Roman, E.
(2004). Diversity of Group A Human Rotavirus Types Circulating over a 4-Year Period in Madrid, Spain. J. Clin. Microbiol.
42: 1609-1613
[Abstract]
[Full Text]
-
Kirkwood, C., Bogdanovic-Sakran, N., Palombo, E., Masendycz, P., Bugg, H., Barnes, G., Bishop, R.
(2003). Genetic and Antigenic Characterization of Rotavirus Serotype G9 Strains Isolated in Australia between 1997 and 2001. J. Clin. Microbiol.
41: 3649-3654
[Abstract]
[Full Text]
-
Martella, V., Terio, V., Del Gaudio, G., Gentile, M., Fiorente, P., Barbuti, S., Buonavoglia, C.
(2003). Detection of the Emerging Rotavirus G9 Serotype at High Frequency in Italy. J. Clin. Microbiol.
41: 3960-3963
[Abstract]
[Full Text]
-
Laird, A. R., Gentsch, J. R., Nakagomi, T., Nakagomi, O., Glass, R. I.
(2003). Characterization of Serotype G9 Rotavirus Strains Isolated in the United States and India from 1993 to 2001. J. Clin. Microbiol.
41: 3100-3111
[Abstract]
[Full Text]
-
Santos, N., Soares, C. C., Volotao, E. M., Albuquerque, M. C. M., Hoshino, Y.
(2003). Surveillance of Rotavirus Strains in Rio de Janeiro, Brazil, from 1997 to 1999. J. Clin. Microbiol.
41: 3399-3402
[Abstract]
[Full Text]
-
Bok, K., Matson, D. O., Gomez, J. A.
(2002). Genetic Variation of Capsid Protein VP7 in Genotype G4 Human Rotavirus Strains: Simultaneous Emergence and Spread of Different Lineages in Argentina. J. Clin. Microbiol.
40: 2016-2022
[Abstract]
[Full Text]